Localization of pharmaceutical manufacturing in Egypt after the outbreak of COVID-19: Part Two

17 October 2022

Since the outbreak of the COVID-19 pandemic, the Egyptian government has offered tremendous opportunities for the localization of the vaccine and biologics’ industry in Egypt, writes The Pharma Letter's local correspondent.

Localization of vaccines and biologics manufacturing is a part of the comprehensive Egypt Vision 2030, which includes a suite of new planning reforms to reshape and develop vaccine and biologics’ industry in Egypt.

Lately, the World Health Organization (WHO) has announced that Egypt's National Regulatory Authority (NRA) for vaccines reached Maturity Level-3 (ML-3), the second highest level in WHO classification of national regulatory systems, which allows local pharmaceutical companies to apply for WHO pre-qualification and WHO Emergency Use Listing of their manufactured products, thus eventually allowing Egypt to export their local vaccines, including COVID-19 vaccines to other countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK